Research ExplorerScientific StaffKatja Weisel Publications

Prof.Dr.med. ID: 6488383

Katja Weisel

graph of relations
Affiliations
1 - 50 out of 244Page size: 50

Publications

  1. 2024

  2. Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

    Salwender, H., Weinhold, N., Benner, A., Miah, K., Merz, M., Haenel, M., Jehn, C., Mai, E., Menis, E., Blau, I., Scheid, C., Hose, D., Seckinger, A., Luntz, S., Besemer, B., Munder, M., Brossart, P., Glass, B., Lindemann, H-W., Weisel, K., Hanoun, C., Schnitzler, P., Klemm, S., Goldschmidt, H., Raab, M. & Elmaagacli, A., 12.2024, In: HEMATOLOGY. 29, 1, p. 2320006

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    Rodriguez-Otero, P., Usmani, S., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X., Pérez-Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M. V., Einsele, H., Minnema, M., Cavo, M., Derman, B. A., Puig, N., Gay, F., Ho, P. J., Chng, W-J., Kastritis, E., Gahrton, G., Weisel, K., Nagarajan, C., Schjesvold, F., Mikhael, J., Costa, L., Raje, N. S., Zamagni, E., Hájek, R., Weinhold, N., Yong, K., Ye, J. C., Sidhana, S., Merlini, G., Martin, T., Lin, Y., Chari, A., Popat, R., Kaufman, J. L. & International Myeloma Working Group, 05.2024, In: LANCET ONCOL. 25, 5, p. e205-e216

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  4. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Einsele, H., Moreau, P., Bahlis, N., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., Martinez-Lopez, J., Rodríguez-Otero, P., Dytfeld, D., Diels, J., Strulev, V., Haddad, I., Renaud, T., Ammann, E., Cabrieto, J., Perualila, N., Gan, R., Zhang, Y., Parekh, T., Albrecht, C., Weisel, K. & Mateos, M-V., 04.2024, In: ADV THER. 41, 4, p. 1576-1593 18 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  5. BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report

    Cords, L., Schaefers, C., Kamili, A., Hoffmann, C., Cichutek, S., Haag, F., Polywka, S., Bokemeyer, C., Leypoldt, L. B., Alsdorf, W., Schulze zur Wiesch, J. & Weisel, K. C., 28.03.2024, In: HAEMATOLOGICA.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

    Mai, E. K., Goldschmid, H., Miah, K., Bertsch, U., Besemer, B., Hänel, M., Krzykalla, J., Fenk, R., Schlenzka, J., Munder, M., Dürig, J., Blau, I. W., Huhn, S., Hose, D., Jauch, A., Kunz, C., Mann, C., Weinhold, N., Scheid, C., Schroers, R., von Metzler, I., Schieferdecker, A., Thomalla, J., Reimer, P., Mahlberg, R., Graeven, U., Kremers, S., Martens, U. M., Kunz, C., Hensel, M., Benner, A., Seidel-Glätzer, A., Weisel, K. C., Raab, M. S., Salwender, H. J. & German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators, 02.2024, In: LANCET HAEMATOL. 11, 2, p. e101-e113

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

    Leypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., Ko, Y-D., de Wit, M., Salwender, H., Scheid, C., Graeven, U., Peceny, R., Staib, P., Dieing, A., Einsele, H., Jauch, A., Hundemer, M., Zago, M., Požek, E., Benner, A., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 01.01.2024, In: J CLIN ONCOL. 42, 1, p. 26-37 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2023

  9. Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials

    Laane, E., Salek, S., Oliva, E. N., Bennink, C., Clavreul, S., Richardson, P. G., Scheid, C., Weisel, K., Ionova, T. & European Hematology Association Specialized Working Group on Quality of Life and Symptoms, 08.12.2023, In: CANCERS. 15, 24, 5764.

    Research output: SCORING: Contribution to journal › Guideline, recommendation, statement › Research › peer-review

  10. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure

    Davies, F. E., Leleu, X., Vogel, P., Dhanasiri, S., Le Nouveau, P. & Weisel, K., 11.2023, In: CL LYMPH MYELOM LEUK. 23, 11, p. 829-837.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

    Dimopoulos, M. A., Hungria, V. T. M., Radinoff, A., Delimpasi, S., Mikala, G., Masszi, T., Li, J., Capra, M., Maiolino, A., Pappa, V., Chraniuk, D., Osipov, I., Leleu, X., Low, M., Matsumoto, M., Sule, N., Li, M., McKeown, A., He, W., Bright, S., Currie, B., Perera, S., Boyle, J., Roy-Ghanta, S., Opalinska, J. & Weisel, K., 10.2023, In: LANCET HAEMATOL. 10, 10, p. e801-e812

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

    Leypoldt, L. B., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M. S., Nogai, A., Khandanpour, C., Runde, V., Jauch, A., Zago, M., Martus, P., Goldschmidt, H., Bokemeyer, C., Dimopoulos, M. A. & Weisel, K. C., 21.09.2023, In: CANCERS. 15, 18, 4667.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  13. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients

    Avivi, I., Vesole, D. H., Davila-Valls, J., Usnarska-Zubkiewicz, L., Olszewska-Szopa, M., Milunovic, V., Baumert, B., Osękowska, B., Kopińska, A., Gentile, M., Puertas-Martinez, B., Robak, P., Crusoe, E., Rodriguez-Lobato, L. G., Gajewska, M., Varga, G., Delforge, M., Cohen, Y., Gozzetti, A., Pena, C., Shustik, C., Mikala, G., Zalac, K., Alexander, H. D., Barth, P., Weisel, K., Martínez-López, J., Waszczuk-Gajda, A., Krzystański, M. & Jurczyszyn, A., 01.09.2023, In: CANCERS. 15, 17, 4359.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  14. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Ramasamy, K., Avet-Loiseau, H., Hveding Blimark, C., Delforge, M., Gay, F., Manier, S., Martinez-Lopez, J., Mateos, M. V., Mohty, M., van de Donk, N. W. C. J. & Weisel, K., 09.2023, In: HEMASPHERE. 7, 9, p. e942

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  15. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis

    Manier, S., Dimopoulos, M., Hulin, C., Leleu, X., Delforge, M., Weisel, K., Mouro, J., Costa, B., Sturniolo, M. & Facon, T., 09.2023, In: CL LYMPH MYELOM LEUK. 23, 9, p. e297-e306.e1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  16. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

    Mateos, M-V., Weisel, K., Martin, T., Berdeja, J. G., Jakubowiak, A., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., Thilakarathne, P., Perualila, N. J., Cabrieto, J., Haefliger, B., Erler-Yates, N., Hague, C., Jackson, C. C., Schecter, J. M., Strulev, V., Nesheiwat, T., Pacaud, L., Einsele, H. & Moreau, P., 01.08.2023, In: HAEMATOLOGICA. 108, 8, p. 2192-2204 13 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  17. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Usmani, S. Z., Quach, H., Mateos, M-V., Landgren, O., Leleu, X., Siegel, D. S., Weisel, K. C., Shu, X., Li, C. & Dimopoulos, M. A., 25.07.2023, In: BLOOD ADV. 7, 14, p. 3739-3748 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  18. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., Weisel, K. C., Badros, A. Z., Beksac, M., Hillengass, J., Mohty, M., Ho, P. J., Ntanasis-Stathopoulos, I., Mateos, M-V., Richardson, P., Blade, J., Moreau, P., San-Miguel, J., Munshi, N., Rajkumar, S. V., Durie, B. G. M., Ludwig, H., Terpos, E. & International Myeloma Working Group, 07.2023, In: LANCET ONCOL. 24, 7, p. e293-e311

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  19. What do hematologists and oncologists consider necessary for their career?: Results of an online survey in Germany, Austria and Switzerland

    Giesler, M., Busson-Spielberger, M., Miemietz, B., de Wit, M., Weisel, K. & Lüftner, D., 07.2023, In: J CANCER RES CLIN. 149, 8, p. 5331-5344 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  20. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Ludwig, H., Terpos, E., van de Donk, N., Mateos, M-V., Moreau, P., Dimopoulos, M-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M. & Sonneveld, P., 06.2023, In: LANCET ONCOL. 24, 6, p. e255-e269

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  21. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

    Moreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., De Stefano, V., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., Leleu, X., Weisel, K., Ghilotti, F., Diels, J., Elsada, A., Morano, R., Strulev, V., Pei, L., Kobos, R., Smit, J., Slavcev, M. & Mateos, M-V., 05.2023, In: ADV THER. 40, 5, p. 2412-2425 14 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  22. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Mateos, M-V., Chari, A., Usmani, S. Z., Goldschmidt, H., Weisel, K., Qi, K., Londhe, A., Nair, S., Lin, X., Pei, L., Ammann, E., Kobos, R., Smit, J., Parekh, T., Marshall, A., Slavcev, M. & Moreau, P., 05.2023, In: CL LYMPH MYELOM LEUK. 23, 5, p. 385-393 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  23. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma

    Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K., Benner, A., Becker, N., Moehler, T., Metzler, I., Khandanpour, C., Seidel-Glaetzer, A., Trautmann-Grill, K., Kortüm, K. M., Müller-Tidow, C., Mechtersheimer, G., Goeppert, B., Stenzinger, A., Weinhold, N., Goldschmidt, H., Weisel, K. C. & Raab, M. S., 06.04.2023, In: BLOOD. 141, 14, p. 1685-1690 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  24. Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID-19 in a tertiary center - A monocentric analysis

    Schaefers, C., Paulsen, F-O., Frenzel, C., Weisel, K., Bokemeyer, C. & Seidel, C., 04.2023, In: BRIT J HAEMATOL. 201, 2, p. 222-226 5 p.

    Research output: SCORING: Contribution to journal › Short publication › Research › peer-review

  25. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

    Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., Perrot, A., Weisel, K., Raje, N., Macro, M., Frenzel, L., Leleu, X., Wang, J., Rampelbergh, R. V., Uhlar, C. M., Vermeulen, J., Duran, J., Borgsten, F. & Usmani, S. Z., 04.2023, In: FUTURE ONCOL. 19, 13, p. 887-895 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  26. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M-V., Mark, T. M., Levin, M-D., Ahmadi, T., Qin, X., Garvin Mayo, W., Gai, X., Carey, J., Carson, R. & Spencer, A., 10.03.2023, In: J CLIN ONCOL. 41, 8, p. 1600-1609 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  27. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

    Weisel, K., Dimopoulos, M. A., San-Miguel, J., Paner, A., Engelhardt, M., Taylor, F., Lord-Bessen, J., Yip, C., Greenwood, M., Tang, J. & Cavo, M., 03.2023, In: HEMASPHERE. 7, 3, p. e843

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  28. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

    Thompson, M. A., Boccadoro, M., Leleu, X., Vela-Ojeda, J., van Rhee, F., Weisel, K. C., Rifkin, R. M., Usmani, S. Z., Hájek, R., Cook, G., Abonour, R., Armour, M., Morgan, K. E., Yeh, S-P., Costello, C. L., Berdeja, J. G., Davies, F. E., Zonder, J. A., Lee, H. C., Omel, J., Spencer, A., Terpos, E., Hungria, V. T. M., Puig, N., Fu, C., Ferrari, R. H., Ren, K., Stull, D. M. & Chari, A., 03.2023, In: CL LYMPH MYELOM LEUK. 23, 3, p. e171-e181

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  29. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry

    Lee, H. C., Ramasamy, K., Weisel, K., Abonour, R., Hardin, J. W., Rifkin, R. M., Ailawadhi, S., Terebelo, H. R., Durie, B. G. M., Tang, D., Joshi, P., Liu, L., Jou, Y-M., Che, M., Hernandez, G., Narang, M., Toomey, K., Gasparetto, C., Wagner, L. I. & Jagannath, S., 02.2023, In: CL LYMPH MYELOM LEUK. 23, 2, p. 112-122 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  30. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

    Mai, E. K., Huhn, S., Miah, K., Poos, A. M., Scheid, C., Weisel, K. C., Bertsch, U., Munder, M., Berlanga, O., Hose, D., Seckinger, A., Jauch, A., Blau, I. W., Hänel, M., Salwender, H. J., Benner, A., Raab, M. S., Goldschmidt, H. & Weinhold, N., 04.01.2023, In: BLOOD CANCER J. 13, 1, p. 1

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  31. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    Ghandili, S., Alihodzic, D., Wiessner, C., Bokemeyer, C., Weisel, K. & Leypoldt, L. B., 01.2023, In: ANN HEMATOL. 102, 1, p. 117-124 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  32. An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

    Rodríguez Otero, P., Towle, K., Cope, S., Caisip, C., Davies, F. E., Delforge, M., Weisel, K., Marshall, T. S., Karampampa, K., Ayers, D., Mojebi, A., Braverman, J., Farrell, J. & Dhanda, D., 2023, In: LEUKEMIA LYMPHOMA. 64, 11, p. 1864-1869 6 p.

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  33. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

    Emde-Rajaratnam, M., Beck, S., Benes, V., Salwender, H., Bertsch, U., Scheid, C., Hänel, M., Weisel, K., Hielscher, T., Raab, M. S., Goldschmidt, H., Jauch, A., Maes, K., De Bruyne, E., Menu, E., De Veirman, K., Moreaux, J., Vanderkerken, K., Seckinger, A. & Hose, D., 2023, In: FRONT IMMUNOL. 14, p. 1286700

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  34. 2022

  35. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    D'Souza, A., Shah, N., Rodriguez, C., Voorhees, P. M., Weisel, K., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., Polepally, A. R., Talati, C., Lee, S., Jin, Z., Buelow, B., Vij, R. & Kumar, S., 01.11.2022, In: J CLIN ONCOL. 40, 31, p. 3576-3586 11 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  36. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

    Goldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Weinhold, N., Huhn, S., Kriegsmann, K., Luntz, S. P., Holderried, T. A. W., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C. & German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators, 11.2022, In: LANCET HAEMATOL. 9, 11, p. e810-e821

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  37. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

    Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., Abdallah, A-O., Badros, A. Z., Knop, S., Stadtmauer, E. A., Cheng, Y., Amatangelo, M., Chen, M., Nguyen, T. V., Amin, A., Peluso, T. & van de Donk, N. W. C. J., 11.2022, In: LANCET HAEMATOL. 9, 11, p. e822-e832

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  38. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    Hillengass, J., Cohen, A. D., Delforge, M., Einsele, H., Goldschmidt, H., Weisel, K., Raab, M-S., Scheid, C., Schecter, J. M., de Braganca, K. C., Varsos, H., Yeh, T-M., Mistry, P., Roccia, T., Corsale, C., Akram, M., Pacaud, L., Nesheiwat, T., Agha, M. & Cohen, Y. C., 01.10.2022, In: CL LYMPH MYELOM LEUK. 22, Suppl 2, S411.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  39. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Leleu, X., Martin, T., Weisel, K., Schjesvold, F., Iida, S., Malavasi, F., Manier, S., Chang-Ki Min, Ocio, E. M., Pawlyn, C., Perrot, A., Quach, H., Richter, J., Spicka, I., Yong, K. & Richardson, P. G., 10.2022, In: ANN HEMATOL. 101, 10, p. 2123-2137 15 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  40. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

    Costa, L. J., Hari, P., Berdeja, J. G., De Stefano, V., Gay, F., Hooper, B., Bartlett, M., Haltner, A., Rosta, E., Kumar, S., Martin, T., Mateos, M-V., Moreau, P., Usmani, S. Z., Olyslager, Y., Schecter, J. M., Roccia, T., Garrett, A., Lee, S., Nesheiwat, T., Pacaud, L., Zhou, C., Samjoo, I. A., Lin, Y., Diels, J., Valluri, S. & Weisel, K., 10.2022, In: CURR MED RES OPIN. 38, 10, p. 1759-1767 9 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  41. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    Weisel, K., Wadlund, A. O., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N. & Rodriguez-Otero, P., 10.2022, In: EUR J HAEMATOL. 109, 4, p. 388-397 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  42. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Weisel, K., Krishnan, A., Schecter, J. M., Vogel, M., Jackson, C. C., Deraedt, W., Yeh, T-M., Banerjee, A., Yalniz, F., Nesheiwat, T., Van Sanden, S., Diels, J., Valluri, S., Usmani, S. Z., Berdeja, J. G., Jagannath, S. & Martin, T., 09.2022, In: CL LYMPH MYELOM LEUK. 22, 9, p. 690-701 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  43. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    Landgren, O., Weisel, K., Rosinol, L., Touzeau, C., Turgut, M., Hajek, R., Mollee, P., Kim, J. S., Shu, N., Hu, X., Li, C. & Usmani, S. Z., 09.2022, In: BRIT J HAEMATOL. 198, 6, p. 988-993 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  44. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

    Weisel, K., Nooka, A. K., Terpos, E., Spencer, A., Goldschmidt, H., Dirnberger, F., DeCosta, L., Yusuf, A. & Kumar, S., 08.2022, In: LEUKEMIA LYMPHOMA. 63, 8, p. 1887-1896 10 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  45. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

    Modemann, F., Ghandili, S., Schmiedel, S., Weisel, K., Bokemeyer, C. & Fiedler, W., 29.07.2022, In: CANCERS. 14, 15, 3711.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  46. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Davies, F. E., Pawlyn, C., Usmani, S. Z., San-Miguel, J. F., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., Sonneveld, P., Stewart, A. K., Bergsagel, P. L., Kaiser, M. F., Weisel, K., Keats, J. J., Mikhael, J. R., Morgan, K. E., Ghobrial, I. M., Orlowski, R. Z., Landgren, C. O., Gay, F., Caers, J., Chng, W. J., Chari, A., Walker, B. A., Kumar, S. K., Costa, L. J., Anderson, K. C. & Morgan, G. J., 06.07.2022, In: BLOOD CANCER DISCOV. 3, 4, p. 273-284 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  47. Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study

    Schönlein, M., Wrage, V., Ghandili, S., Mellinghoff, S. C., Brehm, T. T., Leypoldt, L. B., Utz, N., Schrader, R. M., Alsdorf, W., Börschel, N., Bußmann, L., Schönrock, M., Perlick, D., Schön, G., Verpoort, K., Lütgehetmann, M., Schulze Zur Wiesch, J., Weisel, K. C., Bokemeyer, C., Schafhausen, P. & Sinn, M., 13.06.2022, In: CANCER CELL. 40, 6, p. 581-583 3 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

  48. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K. & ELOQUENT-1 investigators, 06.2022, In: LANCET HAEMATOL. 9, 6, p. e403-e414

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  49. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Mateos, M-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Perrot, A., Benjamin, R., van de Donk, N. W. C. J., Ocio, E. M., Scheid, C., Gay, F., Roeloffzen, W., Rodriguez-Otero, P., Broijl, A., Potamianou, A., Sakabedoyan, C., Semerjian, M., Keim, S., Strulev, V., Schecter, J. M., Vogel, M., Wapenaar, R., Nesheiwat, T., San-Miguel, J., Sonneveld, P., Einsele, H. & Moreau, P., 05.2022, In: LEUKEMIA. 36, 5, p. 1371-1376 6 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  50. Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

    Piechotta, V., Skoetz, N., Engelhardt, M., Einsele, H., Goldschmidt, H., Scheid, C. & guideline group, 08.04.2022, In: DTSCH ARZTEBL INT. 119, 14, p. 253-260 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  51. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

    Facon, T., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., Goldschmidt, H., Quach, H., Mohty, M., Venner, C. P., Weisel, K., Raje, N., Hebraud, B., Belhadj-Merzoug, K., Benboubker, L., Decaux, O., Manier, S., Caillot, D., Ukropec, J., Pei, H., Van Rampelbergh, R., Uhlar, C. M., Kobos, R. & Zweegman, S., 04.2022, In: LEUKEMIA. 36, 4, p. 1066-1077 12 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  52. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies

    Modemann, F., Niederwieser, C., Weisel, K., Bokemeyer, C., Fiedler, W. & Ghandili, S., 03.2022, In: LEUKEMIA LYMPHOMA. 63, 3, p. 664-671 8 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  53. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

    Leypoldt, L. B., Besemer, B., Asemissen, A. M., Hänel, M., Blau, I. W., Görner, M., Ko, Y-D., Reinhardt, H. C., Staib, P., Mann, C., Lutz, R., Munder, M., Graeven, U., Peceny, R., Salwender, H., Jauch, A., Zago, M., Benner, A., Tichy, D., Bokemeyer, C., Goldschmidt, H. & Weisel, K. C., 03.2022, In: LEUKEMIA. 36, 3, p. 885-888 4 p.

    Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Previous 1 2 3 4 5 Next